Parametrica Management Ltd Has $379,000 Position in Abbott Laboratories (ABT)

Parametrica Management Ltd lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 59.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,807 shares of the healthcare product maker’s stock after acquiring an additional 2,922 shares during the period. Parametrica Management Ltd’s holdings in Abbott Laboratories were worth $379,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. State Street Corp boosted its stake in shares of Abbott Laboratories by 18.9% during the first quarter. State Street Corp now owns 80,499,469 shares of the healthcare product maker’s stock valued at $3,574,987,000 after acquiring an additional 12,806,535 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Abbott Laboratories by 11.0% during the first quarter. Bank of New York Mellon Corp now owns 33,796,869 shares of the healthcare product maker’s stock valued at $1,500,920,000 after acquiring an additional 3,344,508 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Abbott Laboratories by 33.8% during the first quarter. Ameriprise Financial Inc. now owns 8,823,399 shares of the healthcare product maker’s stock valued at $391,841,000 after acquiring an additional 2,231,316 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Abbott Laboratories by 20.1% during the first quarter. Legal & General Group Plc now owns 8,550,357 shares of the healthcare product maker’s stock valued at $379,731,000 after acquiring an additional 1,433,093 shares during the last quarter. Finally, Boston Partners boosted its stake in shares of Abbott Laboratories by 5,663.7% during the first quarter. Boston Partners now owns 8,212,035 shares of the healthcare product maker’s stock valued at $364,696,000 after acquiring an additional 8,069,557 shares during the last quarter. 71.66% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories (NYSE ABT) traded up 1.03% during trading on Friday, hitting $52.02. The stock had a trading volume of 6,221,827 shares. The firm’s 50 day moving average is $49.81 and its 200 day moving average is $46.69. Abbott Laboratories has a 1-year low of $37.38 and a 1-year high of $52.15. The firm has a market cap of $90.38 billion, a price-to-earnings ratio of 72.86 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The firm had revenue of $6.64 billion for the quarter, compared to the consensus estimate of $6.63 billion. During the same quarter in the previous year, the company posted $0.55 earnings per share. The business’s quarterly revenue was up 24.5% compared to the same quarter last year. On average, analysts anticipate that Abbott Laboratories will post $2.49 earnings per share for the current year.

In other Abbott Laboratories news, insider Hubert L. Allen sold 4,600 shares of the business’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $50.79, for a total value of $233,634.00. Following the transaction, the insider now owns 105,479 shares in the company, valued at $5,357,278.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jared Watkin sold 552 shares of the business’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $47.97, for a total value of $26,479.44. Following the completion of the transaction, the insider now owns 47,090 shares in the company, valued at approximately $2,258,907.30. The disclosure for this sale can be found here. Insiders sold 218,702 shares of company stock worth $10,837,658 in the last 90 days. Corporate insiders own 0.76% of the company’s stock.

A number of analysts recently commented on ABT shares. Wells Fargo & Company reaffirmed an “outperform” rating and set a $54.00 price objective (up previously from $47.50) on shares of Abbott Laboratories in a research note on Friday, June 30th. Zacks Investment Research raised Abbott Laboratories from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a research note on Tuesday, May 16th. TheStreet raised Abbott Laboratories from a “c+” rating to a “b” rating in a research note on Monday, July 3rd. Barclays PLC reaffirmed an “overweight” rating and set a $57.00 price objective (up previously from $52.00) on shares of Abbott Laboratories in a research note on Saturday, July 22nd. Finally, BMO Capital Markets reaffirmed a “hold” rating and set a $48.00 price objective on shares of Abbott Laboratories in a research note on Tuesday, July 11th. Seven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $52.50.

WARNING: This news story was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://sportsperspectives.com/2017/09/10/parametrica-management-ltd-has-379000-position-in-abbott-laboratories-abt.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply